Literature DB >> 7803789

Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity.

L V Rao1, O Nordfang, A D Hoang, U R Pendurthi.   

Abstract

Recent studies have shown that antithrombin III (AT III)/heparin is capable of inhibiting the catalytic activity of factor VIIa bound either to relipidated tissue factor (TF) in suspension or to TF expressed on cell surfaces. We report studies of the mechanism of which by AT III inhibits factor VIIa bound to cell surface TF and compare this inhibitory mechanism with that of tissue factor pathway inhibitor (TFPI)-induced inhibition of factor VIIa/TF. AT III alone and AT III/heparin to a greater extent reduced factor VIIa bound to cell surface TF. Our data show that the decrease in the amount of factor VIIa associated with cell surface TF in the presence of AT III was the result of (1) accelerated dissociation of factor VIIa from cell surface TF after the binding of AT III to factor VIIa/TF complexes and (2) the inability of the resultant free factor VIIa-AT III complexes to bind effectively to a new cell surface TF site. Binding of TFPI/factor Xa to cell surface factor VIIa/TF complexes markedly decreased the dissociation of factor VIIa from the resultant quaternary complex of factor VIIa/TF/TFPI/factor Xa. Addition of high concentrations of factor VIIa could reverse the AT III-induced inhibition of cell surface factor VIIa/TF activity but not TFPI/factor Xa-induced inhibition of factor VIIa/TF activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7803789

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin.

Authors:  Richard A Faaij; Jacobus Burggraaf; Rik C Schoemaker; Rik de Greef; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.

Authors:  R A Faaij; J Burggraaf; R C Schoemaker; R G M Van Amsterdam; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

3.  Population pharmacokinetics of human antithrombin concentrate in paediatric patients.

Authors:  Brady S Moffett; Rosa Diaz; Marianne Galati; Donald Mahoney; Jun Teruya; Donald L Yee
Journal:  Br J Clin Pharmacol       Date:  2017-08-11       Impact factor: 4.335

4.  Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.

Authors:  T Knudsen; A T Kristensen; T C Nichols; H Agersø; A L Jensen; M Kjalke; M Ezban; M Tranholm
Journal:  Haemophilia       Date:  2011-06-06       Impact factor: 4.287

5.  Plasminogen activator inhibitor-1 inhibits factor VIIa bound to tissue factor.

Authors:  P Sen; A A Komissarov; G Florova; S Idell; U R Pendurthi; L Vijaya Mohan Rao
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

6.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

7.  Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.

Authors:  N C Olson; L M Raffield; L A Lange; E M Lange; W T Longstreth; G Chauhan; S Debette; S Seshadri; A P Reiner; R P Tracy
Journal:  J Thromb Haemost       Date:  2017-12-08       Impact factor: 5.824

8.  In vivo effect of adhesion inhibitor heparin on Legionella pneumophila pathogenesis in a murine pneumonia model.

Authors:  Florence Ader; Rozenn Le Berre; Rémi Fackeure; Dominique Raze; Franco Dante Menozzi; Nathalie Viget; Karine Faure; Eric Kipnis; Benoît Guery; Sophie Jarraud; Jerome Etienne; Christian Chidiac
Journal:  Intensive Care Med       Date:  2008-03-26       Impact factor: 17.440

Review 9.  Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis.

Authors:  Steven M Opal; Charles T Esmon
Journal:  Crit Care       Date:  2002-12-20       Impact factor: 9.097

Review 10.  Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  Biomark Cancer       Date:  2015-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.